224 related articles for article (PubMed ID: 28252528)
1. Effects of pitavastatin and pravastatin on markers of immune activation and arterial inflammation in HIV.
Toribio M; Fitch KV; Sanchez L; Burdo TH; Williams KC; Sponseller CA; McCurdy Pate M; Aberg JA; Zanni MV; Grinspoon SK
AIDS; 2017 Mar; 31(6):797-806. PubMed ID: 28252528
[TBL] [Abstract][Full Text] [Related]
2. Pitavastatin versus pravastatin in adults with HIV-1 infection and dyslipidaemia (INTREPID): 12 week and 52 week results of a phase 4, multicentre, randomised, double-blind, superiority trial.
Aberg JA; Sponseller CA; Ward DJ; Kryzhanovski VA; Campbell SE; Thompson MA
Lancet HIV; 2017 Jul; 4(7):e284-e294. PubMed ID: 28416195
[TBL] [Abstract][Full Text] [Related]
3. Greater remnant lipoprotein cholesterol reduction with pitavastatin compared with pravastatin in HIV-infected patients.
Joshi PH; Miller PE; Martin SS; Jones SR; Massaro JM; D'Agostino RB; Kulkarni KR; Sponseller C; Toth PP
AIDS; 2017 Apr; 31(7):965-971. PubMed ID: 28121706
[TBL] [Abstract][Full Text] [Related]
4. Pitavastatin 4 mg Provides Significantly Greater Reduction in Remnant Lipoprotein Cholesterol Compared With Pravastatin 40 mg: Results from the Short-term Phase IV PREVAIL US Trial in Patients With Primary Hyperlipidemia or Mixed Dyslipidemia.
Miller PE; Martin SS; Joshi PH; Jones SR; Massaro JM; D'Agostino RB; Sponseller CA; Toth PP
Clin Ther; 2016 Mar; 38(3):603-9. PubMed ID: 26922296
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the lipid-lowering effects of pitavastatin 4 mg versus pravastatin 40 mg in adults with primary hyperlipidemia or mixed (combined) dyslipidemia: a Phase IV, prospective, US, multicenter, randomized, double-blind, superiority trial.
Sponseller CA; Morgan RE; Kryzhanovski VA; Campbell SE; Davidson MH
Clin Ther; 2014 Aug; 36(8):1211-22. PubMed ID: 24998014
[TBL] [Abstract][Full Text] [Related]
6. Effects of Pitavastatin on Lipid Profiles in HIV-Infected Patients with Dyslipidemia and Receiving Atazanavir/Ritonavir: A Randomized, Double-Blind, Crossover Study.
Wongprikorn A; Sukasem C; Puangpetch A; Numthavej P; Thakkinstian A; Kiertiburanakul S
PLoS One; 2016; 11(6):e0157531. PubMed ID: 27304841
[TBL] [Abstract][Full Text] [Related]
7. Assessing statin effects on cardiovascular pathways in HIV using a novel proteomics approach: Analysis of data from INTREPID, a randomized controlled trial.
Toribio M; Fitch KV; Stone L; Zanni MV; Lo J; de Filippi C; Sponseller CA; Lee H; Grundberg I; Thompson MA; Aberg JA; Grinspoon SK
EBioMedicine; 2018 Sep; 35():58-66. PubMed ID: 30174281
[TBL] [Abstract][Full Text] [Related]
8. Effects of Pitavastatin on Coronary Artery Disease and Inflammatory Biomarkers in HIV: Mechanistic Substudy of the REPRIEVE Randomized Clinical Trial.
Lu MT; Ribaudo H; Foldyna B; Zanni MV; Mayrhofer T; Karady J; Taron J; Fitch KV; McCallum S; Burdo TH; Paradis K; Hedgire SS; Meyersohn NM; DeFilippi C; Malvestutto CD; Sturniolo A; Diggs M; Siminski S; Bloomfield GS; Alston-Smith B; Desvigne-Nickens P; Overton ET; Currier JS; Aberg JA; Fichtenbaum CJ; Hoffmann U; Douglas PS; Grinspoon SK;
JAMA Cardiol; 2024 Apr; 9(4):323-334. PubMed ID: 38381407
[TBL] [Abstract][Full Text] [Related]
9. A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance.
Sasaki J; Ikeda Y; Kuribayashi T; Kajiwara K; Biro S; Yamamoto K; Ageta M; Kobori S; Saikawa T; Otonari T; Kono S
Clin Ther; 2008 Jun; 30(6):1089-101. PubMed ID: 18640465
[TBL] [Abstract][Full Text] [Related]
10. Statins for atherosclerotic cardiovascular disease prevention in people living with HIV in Thailand: a cost-effectiveness analysis.
Boettiger DC; Newall AT; Chattranukulchai P; Chaiwarith R; Khusuwan S; Avihingsanon A; Phillips A; Bendavid E; Law MG; Kahn JG; Ross J; Bautista-Arredondo S; Kiertiburanakul S
J Int AIDS Soc; 2020 Jun; 23 Suppl 1(Suppl 1):e25494. PubMed ID: 32562359
[TBL] [Abstract][Full Text] [Related]
11. Pitavastatin: novel effects on lipid parameters.
Chapman MJ
Atheroscler Suppl; 2011 Nov; 12(3):277-84. PubMed ID: 22152282
[TBL] [Abstract][Full Text] [Related]
12. Pitavastatin - results from phase III & IV.
Betteridge J
Atheroscler Suppl; 2010 Dec; 11(3):8-14. PubMed ID: 21193153
[TBL] [Abstract][Full Text] [Related]
13. Pitavastatin shows greater lipid-lowering efficacy over 12 weeks than pravastatin in elderly patients with primary hypercholesterolaemia or combined (mixed) dyslipidaemia.
Stender S; Budinski D; Gosho M; Hounslow N
Eur J Prev Cardiol; 2013 Feb; 20(1):40-53. PubMed ID: 22679249
[TBL] [Abstract][Full Text] [Related]
14. Comparative efficacy of pitavastatin and simvastatin in high-risk patients: a randomized controlled trial.
Eriksson M; Budinski D; Hounslow N
Adv Ther; 2011 Sep; 28(9):811-23. PubMed ID: 21874538
[TBL] [Abstract][Full Text] [Related]
15. The influence of pravastatin and atorvastatin on markers of oxidative stress in hypercholesterolemic humans.
Ky B; Burke A; Tsimikas S; Wolfe ML; Tadesse MG; Szapary PO; Witztum JL; FitzGerald GA; Rader DJ
J Am Coll Cardiol; 2008 Apr; 51(17):1653-62. PubMed ID: 18436117
[TBL] [Abstract][Full Text] [Related]
16. Effects of pitavastatin add-on therapy on chronic kidney disease with albuminuria and dyslipidemia.
Ohsawa M; Tamura K; Wakui H; Kanaoka T; Azushima K; Uneda K; Haku S; Kobayashi R; Ohki K; Haruhara K; Kinguchi S; Toya Y; Umemura S
Lipids Health Dis; 2015 Dec; 14():161. PubMed ID: 26645467
[TBL] [Abstract][Full Text] [Related]
17. Differential Reduction in Monocyte Activation and Vascular Inflammation With Integrase Inhibitor-Based Initial Antiretroviral Therapy Among HIV-Infected Individuals.
Hileman CO; Kinley B; Scharen-Guivel V; Melbourne K; Szwarcberg J; Robinson J; Lederman MM; Mccomsey GA
J Infect Dis; 2015 Aug; 212(3):345-54. PubMed ID: 25583168
[TBL] [Abstract][Full Text] [Related]
18. Treatment with pravastatin and fenofibrate improves atherogenic lipid profiles but not inflammatory markers in ACTG 5087.
Fichtenbaum CJ; Yeh TM; Evans SR; Aberg JA
J Clin Lipidol; 2010; 4(4):279-87. PubMed ID: 20824151
[TBL] [Abstract][Full Text] [Related]
19. Oxidized low-density lipoprotein in children with familial hypercholesterolemia and unaffected siblings: effect of pravastatin.
Rodenburg J; Vissers MN; Wiegman A; Miller ER; Ridker PM; Witztum JL; Kastelein JJ; Tsimikas S
J Am Coll Cardiol; 2006 May; 47(9):1803-10. PubMed ID: 16682304
[TBL] [Abstract][Full Text] [Related]
20. Effects of pravastatin, phytosterols, and combination therapy on lipid profile in HIV-infected patients: an open-labelled, randomized cross-over study.
Kietsiriroje N; Leelawattana R
BMC Res Notes; 2015 Jul; 8():294. PubMed ID: 26148680
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
